INT232510

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 18
Total Number 18
Disease Relevance 20.27
Pain Relevance 2.54

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytoplasmic membrane-bounded vesicle (CXCR4) plasma membrane (CXCR4) cytoplasm (CXCR4)
signal transducer activity (CXCR4)
Anatomy Link Frequency
T cells 4
blood 2
monocytes 2
CXCR4 (Homo sapiens)
Pain Link Frequency Relevance Heat
chemokine 341 100.00 Very High Very High Very High
Inflammation 195 100.00 Very High Very High Very High
antagonist 130 100.00 Very High Very High Very High
cytokine 98 100.00 Very High Very High Very High
agonist 66 99.60 Very High Very High Very High
COX-2 inhibitor 36 97.56 Very High Very High Very High
Leflunomide 54 97.00 Very High Very High Very High
Potency 13 71.44 Quite High
adenocard 104 15.28 Low Low
metalloproteinase 115 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Breast Cancer 325 100.00 Very High Very High Very High
INFLAMMATION 220 100.00 Very High Very High Very High
Cancer 1583 99.96 Very High Very High Very High
Metastasis 562 99.92 Very High Very High Very High
Myelofibrosis 30 99.26 Very High Very High Very High
Colon Cancer 274 99.20 Very High Very High Very High
Osteogenic Sarcomas 26 98.72 Very High Very High Very High
Reprotox - General 1 91 97.52 Very High Very High Very High
Stomach Cancer 26 97.52 Very High Very High Very High
Hypoxia 144 96.64 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
demonstrated the efficacy of strategies designed to reduce CXCR4 expression or
Negative_regulation (reduce) of Gene_expression (expression) of CXCR4
1) Confidence 0.58 Published 2008 Journal PPAR Research Section Body Doc Link PMC2528256 Disease Relevance 1.64 Pain Relevance 0.03
agonist rosiglitazone also decreased CXCR4 expression on human
Negative_regulation (decreased) of Gene_expression (expression) of CXCR4 associated with agonist
2) Confidence 0.43 Published 2008 Journal PPAR Research Section Body Doc Link PMC2528256 Disease Relevance 1.20 Pain Relevance 0.09
CXCR4 expression in the breast cancer model was accompanied by reduced
Negative_regulation (reduced) of Gene_expression (expression) of CXCR4 associated with breast cancer
3) Confidence 0.43 Published 2008 Journal PPAR Research Section Body Doc Link PMC2528256 Disease Relevance 1.54 Pain Relevance 0.04
analysis, they found that CXCR4 mRNA expression was suppressed by the reintroduction of functional pVHL into
Negative_regulation (suppressed) of Gene_expression (expression) of CXCR4 mRNA
4) Confidence 0.43 Published 2008 Journal PPAR Research Section Body Doc Link PMC2528256 Disease Relevance 1.76 Pain Relevance 0
to suppress CXCR4 expression.
Negative_regulation (suppress) of Gene_expression (expression) of CXCR4
5) Confidence 0.43 Published 2008 Journal PPAR Research Section Abstract Doc Link PMC2528256 Disease Relevance 0.93 Pain Relevance 0.23
The

downregulation of CXCR4 expression by 15dPGJ2 differs from 15 dPGJ2-mediated

Negative_regulation (downregulation) of Gene_expression (expression) of CXCR4
6) Confidence 0.43 Published 2008 Journal PPAR Research Section Body Doc Link PMC2528256 Disease Relevance 0.10 Pain Relevance 0.06
increased pulmonary metastasis, which was reduced with the CXCR4 peptide
Negative_regulation (reduced) of Gene_expression (peptide) of CXCR4 associated with metastasis
7) Confidence 0.43 Published 2008 Journal PPAR Research Section Body Doc Link PMC2528256 Disease Relevance 1.81 Pain Relevance 0.21
mammalian target of rapamycin (mTOR) pathway downstream of CXCR4 was shown to
Negative_regulation (downstream) of Gene_expression (target) of CXCR4
8) Confidence 0.43 Published 2008 Journal PPAR Research Section Body Doc Link PMC2528256 Disease Relevance 1.61 Pain Relevance 0.14
mammalian target of rapamycin (mTOR) pathway downstream of CXCR4 was shown to
Negative_regulation (shown) of Gene_expression (target) of CXCR4
9) Confidence 0.43 Published 2008 Journal PPAR Research Section Body Doc Link PMC2528256 Disease Relevance 1.62 Pain Relevance 0.14
noncompetitive CXCR4 antagonist AMD3100 inhibited tumor growth after
Negative_regulation (inhibited) of Gene_expression (antagonist) of CXCR4 associated with cancer and antagonist
10) Confidence 0.43 Published 2008 Journal PPAR Research Section Body Doc Link PMC2528256 Disease Relevance 1.70 Pain Relevance 0.20
A neutralizing anti-CXCR4 antibody prevented
Negative_regulation (prevented) of Gene_expression (antibody) of CXCR4
11) Confidence 0.43 Published 2008 Journal PPAR Research Section Body Doc Link PMC2528256 Disease Relevance 1.67 Pain Relevance 0.06
noncompetitive CXCR4 antagonist AMD3100 inhibited tumor growth after
Negative_regulation (noncompetitive) of Gene_expression (antagonist) of CXCR4 associated with cancer and antagonist
12) Confidence 0.43 Published 2008 Journal PPAR Research Section Body Doc Link PMC2528256 Disease Relevance 1.69 Pain Relevance 0.20
The time course of the decline in cell-surface CXCR4 protein is slow, reaching
Negative_regulation (reaching) of Gene_expression (slow) of CXCR4 protein
13) Confidence 0.43 Published 2008 Journal PPAR Research Section Body Doc Link PMC2528256 Disease Relevance 0.20 Pain Relevance 0
Linear regression analysis showed a significant negative correlation between age and CD133+CXCR4+CD34- levels (r2?
Negative_regulation (correlation) of Gene_expression (levels) of CXCR4
14) Confidence 0.42 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2377332 Disease Relevance 0.54 Pain Relevance 0
Decreases in expression of CXCR4 were also seen in both CD4 (Figure 4C) and CD8 (Figure 4D) T cells in the leflunomide group at Day 15 (CD4: ?
Negative_regulation (Decreases) of Gene_expression (expression) of CXCR4 in T cells associated with leflunomide
15) Confidence 0.19 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914784 Disease Relevance 0.14 Pain Relevance 0.15
Both methods inhibited gene expression of VEGF-A, VEGF-C (angiogenic molecules), GRO (cytokine with inflammatory and growth-regulatory properties), RANTES (cytokine regulating T cell response) and SDF-1(a ligand for the chemokine receptor CXCR4) even at 24 h PI.
Negative_regulation (inhibited) of Gene_expression (expression) of CXCR4 in T cell associated with chemokine, inflammation and cytokine
16) Confidence 0.15 Published 2010 Journal PLoS Pathogens Section Body Doc Link PMC2820536 Disease Relevance 0.65 Pain Relevance 0.47
HMB-PP-activated monocytes down-modulated surface expression of CXCR4, CCR2, and CCR5 (Fig. 6B; and data not shown), which may have resulted from chemokine-mediated receptor internalization [42].
Negative_regulation (down-modulated) of Gene_expression (expression) of CXCR4 in monocytes associated with chemokine
17) Confidence 0.12 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2637987 Disease Relevance 0.31 Pain Relevance 0.38
The increased number of CD34-positive cells in the peripheral blood of PMF patients has been attributed to the reduced membrane expression of C-X-C chemokine receptor type 4 (CXCR4) [35, 36] which is secondary to increased methylation of the CpG islands of the CXCR4 promoter [37].
Negative_regulation (reduced) of Gene_expression (expression) of CXCR4 in blood associated with chemokine and myelofibrosis
18) Confidence 0.10 Published 2010 Journal Invest New Drugs Section Body Doc Link PMC3003795 Disease Relevance 1.17 Pain Relevance 0.16

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox